Video

Inside Cardiology: Lipid Management in 2021

Author(s):

Patrick Campbell

In this edition of Inside Cardiology, a trio of advisory board members discuss a series of case reports, upcoming and newly released therapies for lipid disorders, and use of telehealth for the management of patients.

Related Videos
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
The APAC Recap: Dyslipidemia at CAPP Live 2024 with Viet Le, DMSc, PA-C | Image Credit: APAC
HCPLive Lipoprotein Apheresis Special Report thumbnail
HCPLive Lipoprotein Apheresis Special Report thumbnail
HCPLive Lipoprotein Apheresis Special Report thumbnail
Steve Nissen, MD | Credit: Cleveland Clinic
Benjamin Scirica, MD | Credit: Brigham and Women's Hospital
Related Content
Stephen Nicholls, MBBS, PhD | Credit: Monash University
November 19th 2024

Muvalaplin, an Oral Lp(a)-Lowering Agent, Shows Promise in Phase 2 KRAKEN Trial

Patrick Campbell
Prof. Kausik Ray: Inclisiran Data at ESC Congress 2020
September 3rd 2020

Prof. Kausik Ray: Inclisiran Data at ESC Congress 2020

Patrick Campbell
COVID-19 Pandemic Linked to 29% Higher Risk of Dyslipidemia, Study Finds| Image Credit: Albert Einstein College of Medicine
November 7th 2024

COVID-19 Pandemic Linked to 29% Higher Risk of Dyslipidemia, Study Finds

Connor Iapoce
The State of Preventive Cardiology
August 28th 2020

The State of Preventive Cardiology

Kevin Kunzmann
Patients with Major Depressive Disorder Have Increased Triglyceride Levels
October 19th 2024

Patients with Major Depressive Disorder Have Increased Triglyceride Levels

Chelsie Derman
AHA Scientific Statement Promotes Expanded Use of Lipoprotein Apheresis | Image Credit: USNews
October 11th 2024

AHA Scientific Statement Promotes Expanded Use of Lipoprotein Apheresis

Connor Iapoce
© 2024 MJH Life Sciences

All rights reserved.